Monday, April 25, 2016 9:26:22 AM
HTTP://theassociationofphysicians.org.uk/files/APAM_2016_Programme.pdf
9:30 a.m.
12) Trovax® And Cyclophosphamide InduceAnti-Tumour Immune ResponsesThat CorrelateWith Prolonged
Survival Of End-Stage Colorectal Cancer Patients
Godkin, A; Pembroke, T; Gallimore, A; Scurr, M
The cytotoxic response to cancer is counteracted by tumour-induced immunosuppression. 54 colorectal cancer patients with
inoperable metastatic disease were randomized to a virus vaccine expressing an oncofetal antigen +/-
cyclophophosphamide to counteract immune regulation. The results of this phase I/II trial demonstrate improved outcome
corresponding to tumour-directed T cell responses.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM